SUC2C Grant to Advance Novel Therapies in Gastroesophageal Cancer

Overview

A 3-year Stand Up To Cancer (SU2C) grant awarded to Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center aims to improve treatment for gastroesophageal cancer patients who do not respond to standard therapies. The collaboration will focus on understanding immune evasion linked to chromosomal instability and developing new therapeutic strategies.

Background

Gastroesophageal cancer accounts for approximately one-third of all cancer-related deaths worldwide. Despite available treatments, about 70% of patients with this cancer type fail to respond, highlighting an urgent need for novel therapies. Chromosomal instability in tumors has been associated with immune suppression, lower T-cell infiltration, and poorer outcomes. Investigating these mechanisms may reveal new targets for therapy, especially in both HER2-negative and HER2-positive patient populations.

Data Highlights

Approximately 33% of global cancer deaths are due to gastrointestinal cancers. About 70% of gastroesophageal cancer patients do not respond to current treatments. Chromosomal instability correlates with decreased intratumoral T-cell infiltration and worse response to immune checkpoint inhibitors.

Key Findings

• The SU2C–Torrey Coast Foundation awarded a 3-year grant to support collaborative research between Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.
• Research will utilize whole-genome sequencing to study chromosomal instability and its role in immune evasion in gastroesophageal cancer.
• Focus will be on identifying immune system targets and potential therapeutic combinations for both HER2-negative and HER2-positive tumors.
• A new clinical trial will be launched to evaluate the efficacy of these novel treatment strategies.
• Access to larger biomarker datasets and clinical trials is expected to accelerate the development of next-generation therapies.

Clinical Implications

Understanding the mechanisms of immune evasion related to chromosomal instability may enable clinicians to better stratify patients and tailor therapies. The identification of new immune targets could improve response rates to immunotherapy in gastroesophageal cancer. The upcoming clinical trial may provide evidence for more effective treatment combinations, particularly for patients resistant to current standards of care.

Conclusion

This SU2C-funded collaboration represents a significant step toward addressing the high unmet need in gastroesophageal cancer by leveraging genomic insights to develop novel immunotherapeutic strategies. The initiative holds promise for improving outcomes in a patient population with historically poor responses to treatment.

References

1. Weill Cornell Medicine & Memorial Sloan Kettering Cancer Center 2024 -- SUC2C Grant Could Facilitate Development of Novel Therapies in Gastroesophageal Cancer